HRP20131017T1 - Spoj kondenziranog prstena i njegove uporabe - Google Patents
Spoj kondenziranog prstena i njegove uporabe Download PDFInfo
- Publication number
- HRP20131017T1 HRP20131017T1 HRP20131017AT HRP20131017T HRP20131017T1 HR P20131017 T1 HRP20131017 T1 HR P20131017T1 HR P20131017A T HRP20131017A T HR P20131017AT HR P20131017 T HRP20131017 T HR P20131017T HR P20131017 T1 HRP20131017 T1 HR P20131017T1
- Authority
- HR
- Croatia
- Prior art keywords
- optionally substituted
- compound according
- compound
- alkoxy
- halogen atom
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 26
- 125000005843 halogen group Chemical group 0.000 claims 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 4
- 238000011321 prophylaxis Methods 0.000 claims 4
- 238000011282 treatment Methods 0.000 claims 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- -1 carboxy, carbamoyl Chemical group 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 2
- 206010003210 Arteriosclerosis Diseases 0.000 claims 2
- 206010008190 Cerebrovascular accident Diseases 0.000 claims 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 2
- 230000002490 cerebral effect Effects 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 210000002824 peroxisome Anatomy 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 claims 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 1
- NGAMDPDNJSGZLR-UHFFFAOYSA-N 3-[2-[4-[[4-[4-(2-hydroxy-2-methylpropoxy)cyclohexyl]-5-oxo-7-propylpyrazolo[1,5-a]pyrimidin-6-yl]methyl]phenyl]phenyl]-2h-1,2,4-oxadiazol-5-one Chemical compound O=C1N(C2CCC(CC2)OCC(C)(C)O)C2=CC=NN2C(CCC)=C1CC(C=C1)=CC=C1C1=CC=CC=C1C1=NC(=O)ON1 NGAMDPDNJSGZLR-UHFFFAOYSA-N 0.000 claims 1
- NMAZGYDYIYLSLJ-UHFFFAOYSA-N 4-{[5-(cyclohexylmethoxy)[1,2,4]triazolo[1,5-a]pyrimidin-7-yl]amino}benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1NC1=CC(OCC2CCCCC2)=NC2=NC=NN12 NMAZGYDYIYLSLJ-UHFFFAOYSA-N 0.000 claims 1
- 102000008873 Angiotensin II receptor Human genes 0.000 claims 1
- 108050000824 Angiotensin II receptor Proteins 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 230000001270 agonistic effect Effects 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (22)
1. Spoj, naznačen time, da je predstavljen formulom (I):
[image]
gdje
R1 je atom vodika, opcijski supstituiran C1-6alkil, opcijski supstituirana 3- do 10-člana nearomatska ciklička skupina ili opcijski supstituirana 5- do 6-člana aromatska ciklička skupina,
R2 je atom vodika, opcijski supstituiran C1-6alkil, opcijski supstituiran C1-6alkoksi, opcijski supstituiran C1-6alkiltio, opcijski supstituiran C1-6alkilsulfmil ili opcijski supstituiran C1-6alkilsulfonil,
R3 je atom vodika, atom halogena, opcijski supstituiran C1-6alkil, opcijski supstituiran C1-6alkoksi,
X, Y i Z su svaki neovisno atom dušika ili CR4 gdje je R4 atom vodika, atom halogena, opcijski supstituiran C1-6alkil, opcijski supstituiran C1-6alkoksi ili opcijski supstituiran C3-6cikloalkil,
W je opcijski supstituiran C1-4alkilen, -O-W'-, -W'-O-, -N(Ra)-W'- ili W'-N(Ra)-, gdje W'je veza ili opcijski supstituiran C1-4alkilen, Ra je atom vodika, opcijski supstituiran C1-6alkil ili opcijski supstituiran C3-6cikloalkil,
A je opcijski supstituiran 5- do 6-člani divalentni aromatski prsten, i
B je acil ili opcijski supstituirana 3- do 10-člana heterociklička skupina, pod uvjetom da kada je B karboksi, karbamoil ili tetrazoil, tada R1 nije atom vodika, ili njegova sol.
2. Spoj prema zahtjevu 1, naznačen time, da R1 je opcijski supstituiran C1-6alkil, opcijski supstituirana 3- do 10-člana nearomatska ciklička skupina ili opcijski supstituirana 5- do 6- člana aromatska ciklička skupina.
3. Spoj prema zahtjevu 2, naznačen time, da X je atom dušika, a Y i Z su svaki CR4, gdje R4 je određen u zahtjevu 1.
4. Spoj prema zahtjevu 2, naznačen time, da X i Z su atomi dušika, a Y je CR4, gdje R4 je određen u zahtjevu 1.
5. Spoj prema zahtjevu 2, naznačen time, da R2 je opcijski supstituiran C1-6alkil.
6. Spoj prema zahtjevu 2, naznačen time, da R3 je atom vodika.
7. Spoj prema zahtjevu 2, naznačen time, da W je opcijski supstituiran C1-4alkilen.
8. Spoj prema zahtjevu 2, naznačen time, da A je opcijski supstituiran fenilen, opcijski supstituiran tiofen-di-il ili opcijski supstituiran piridin-di-il.
9. Spoj prema zahtjevu 1, naznačen time, da W je skupina predstavljena sa
[image]
gdje i je -O- ili -S-, j je -C(=O)-, -C(=S)- ili -S(O)m, a m je cijeli broj 0, 1 ili 2.
10. Spoj prema zahtjevu 1, naznačen time, da je taj spoj predstavljen formulom
[image]
gdje
R1 je C3-8cikloalkil opcijski supstituiran s C1-6alkoksi koji je opcijski supstituiran s 1) atomom halogena, 2) cijano, 3) hidroksi ili 4) C1-6alkoksi koji je opcijski supstituiran s atomom halogena,
R2 je C1-6alkil,
A je fenilen opcijski supstituiran s atomom halogena, i
R4 su svaki neovisno atom vodika ili metil.
11. Spoj prema zahtjevu 1, naznačen time, da je taj spoj predstavljen formulom
[image]
gdje
R1 je C3-8cikloalkil opcijski supstituiran s C1-6alkoksi koji je opcijski supstituiran s 1) atomom halogena, 2) cijano, 3) hidroksi ili 4) C1-6alkoksi koji je opcijski supstituiran s atomom halogena,
R2 je C1-6alkil,
A je fenilen opcijski supstituiran s atomom halogena, i
R4 je atom vodika ili metil.
12. Spoj prema zahtjevu 1, naznačen time, da je taj spoj predstavljen formulom
[image]
gdje
R1 je cikloheksil opcijski supstituiran s C1-6alkoksi koji je opcijski supstituiran s hidroksi, i
R2je C1-6alkil.
13. Spoj prema zahtjevu 1, naznačen time, da je taj spoj predstavljen formulom
[image]
gdje
R1 je cikloheksil opcijski supstituiran s C1-6alkoksi koji je opcijski supstituiran s hidroksi,
R2 je C1-6alkil, i
A je fenilen opcijski supstituiran s atomom halogena.
14. Spoj prema zahtjevu 1, naznačen time, da je taj spoj 4-[trans-4-(2-hidroksi-2- metilpropoksi)cikloheksil]-6-{[2'-(5-okso-4,5-dihidro-1,2,4-oksadiazol-3-il)bifenil-4-il]metil}-7-propilpirazolo[1,5-a]pirimidin-5(4H)-on ili njegova sol.
15. Spoj prema zahtjevu 1, naznačen time, da je taj spoj 6-{[3-fluoro-2'-(5-okso-4,5-dihidro-1,2,4-oksadiazol-3-il)bifenil-4-il]metil}-4-[trans-4-(2-hidroksi-1,2-dimetilpropoksi)cikloheksil]-7-propil[1,2,4]triazolo[1,5-a]pirimidin-5(4H)-on ili njegova sol.
16. Lijek, naznačen time, da obuhvaća spoj prema bilo kojem od zahtjeva 1 do 15.
17. Lijek prema zahtjevu 16, naznačen time, da sadrži receptor angiotenzina II antagonističkog djelovanja i prolifarativno aktivirani y receptor peroksisoma agonističkog djelovanja.
18. Lijek prema zahtjevu 16, naznačen time, da je on sredstvo za profilaksu ili liječenje cirkulacijske bolesti.
19. Lijek prema zahtjevu 16, naznačen time, da je on sredstvo za profilaksu ili liječenje hipertenzije, srčane bolesti, arterioskleroze, bubrežne bolesti, oftalmijske bolesti, bolesti jetre, cerebralne apopleksije, hiperlipidemije, pretilosti i/ili dijabetesa.
20. Spoj prema bilo kojem od zahtjeva 1 do 15, naznačen time, da se on upotrebljava kao antagonist receptora angiotenzina II i agonist y receptora proliferacijski aktiviranog peroksisoma.
21. Spoj prema bilo kojem od zahtjeva 1 do 15, naznačen time, da se on upotrebljava u profilaksi ili liječenju cirkulacijske bolesti.
22. Spoj prema bilo kojem od zahtjeva 1 do 15, naznačen time, da se on upotrebljava u profilaksi ili liječenju hipertenzije, srčane bolesti, arterioskleroze, bubrežne bolesti, oftalmijske bolesti, bolesti jetre, cerebralne apopleksije, hiperlipidemije, pretilosti i/ili dijabetesa.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2009020720 | 2009-01-30 | ||
PCT/JP2010/051651 WO2010087515A1 (en) | 2009-01-30 | 2010-01-29 | Fused ring compound and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20131017T1 true HRP20131017T1 (hr) | 2013-12-06 |
Family
ID=42026435
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20131017AT HRP20131017T1 (hr) | 2009-01-30 | 2013-10-25 | Spoj kondenziranog prstena i njegove uporabe |
Country Status (37)
Country | Link |
---|---|
US (4) | US8592431B2 (hr) |
EP (1) | EP2384327B1 (hr) |
JP (2) | JP4892649B1 (hr) |
KR (1) | KR20110113758A (hr) |
CN (2) | CN103788097B (hr) |
AR (1) | AR075344A1 (hr) |
AU (1) | AU2010208863A1 (hr) |
CA (1) | CA2750710C (hr) |
CL (1) | CL2011001848A1 (hr) |
CO (1) | CO6362011A2 (hr) |
CR (1) | CR20110463A (hr) |
CY (1) | CY1114530T1 (hr) |
DK (1) | DK2384327T3 (hr) |
DO (1) | DOP2011000249A (hr) |
EA (1) | EA019823B1 (hr) |
EC (1) | ECSP11011294A (hr) |
ES (1) | ES2433225T3 (hr) |
GE (1) | GEP20135961B (hr) |
HK (1) | HK1162505A1 (hr) |
HR (1) | HRP20131017T1 (hr) |
IL (1) | IL214283A0 (hr) |
MA (1) | MA33071B1 (hr) |
ME (1) | ME01621B (hr) |
MX (1) | MX2011008058A (hr) |
MY (1) | MY152946A (hr) |
NZ (1) | NZ594606A (hr) |
PE (1) | PE20120593A1 (hr) |
PL (1) | PL2384327T3 (hr) |
PT (1) | PT2384327E (hr) |
RS (1) | RS53012B (hr) |
SG (1) | SG173135A1 (hr) |
SI (1) | SI2384327T1 (hr) |
TN (1) | TN2011000368A1 (hr) |
TW (2) | TWI468410B (hr) |
UY (1) | UY32409A (hr) |
WO (1) | WO2010087515A1 (hr) |
ZA (1) | ZA201105867B (hr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2384327T3 (pl) | 2009-01-30 | 2013-12-31 | Takeda Pharmaceuticals Co | Związki ze skondensowanym pierścieniem i ich zastosowanie |
PL2655375T3 (pl) | 2010-12-23 | 2015-05-29 | Sanofi Sa | Pochodne pirymidynonu, ich wytwarzanie i ich farmaceutyczne zastosowanie |
CZ304252B6 (cs) * | 2011-04-11 | 2014-01-29 | Zentiva, K. S. | Způsob výroby 2-ethoxy-1-((2´-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)bifenyl-4-yl)methyl)-1H-benzo[d]imidazol-7-karboxylátů a jejich převedení na azilsartan |
CN109563100B (zh) | 2016-06-20 | 2021-08-27 | 诺华股份有限公司 | 三唑并嘧啶化合物的晶体形式 |
CN111107744A (zh) | 2017-09-26 | 2020-05-05 | 埃科莱布美国股份有限公司 | 酸性/阴离子抗微生物组合物和杀病毒组合物以及其用途 |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
WO2020168197A1 (en) | 2019-02-15 | 2020-08-20 | Incyte Corporation | Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors |
TW202100520A (zh) | 2019-03-05 | 2021-01-01 | 美商英塞特公司 | 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物 |
US11919904B2 (en) | 2019-03-29 | 2024-03-05 | Incyte Corporation | Sulfonylamide compounds as CDK2 inhibitors |
US11440914B2 (en) | 2019-05-01 | 2022-09-13 | Incyte Corporation | Tricyclic amine compounds as CDK2 inhibitors |
WO2020223558A1 (en) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Tricyclic amine compounds as cdk2 inhibitors |
KR20220064369A (ko) | 2019-08-14 | 2022-05-18 | 인사이트 코포레이션 | Cdk2 저해제로서의 이미다졸릴 피리디미딘일아민 화합물 |
BR112022006977A2 (pt) | 2019-10-11 | 2022-09-20 | Incyte Corp | Aminas bicíclicas como inibidores de cdk2 |
CN112745319B (zh) * | 2019-10-30 | 2022-06-17 | 中国科学院上海药物研究所 | 一类取代三环结构的化合物、其制备方法及用途 |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2672892B1 (fr) | 1991-02-20 | 1994-01-14 | Synthelabo | Derives de 4-pyrimidinones, leur preparation et leur application en therapeutique. |
US5472967A (en) | 1991-02-20 | 1995-12-05 | Synthelabo | 4-pyrimidinone derivatives their preparation and their application in therapy |
IL102183A (en) | 1991-06-27 | 1999-11-30 | Takeda Chemical Industries Ltd | The heterocyclic compounds are converted into biphenyl groups, their production and the pharmaceutical compositions containing them |
TW251288B (hr) * | 1991-06-27 | 1995-07-11 | Takeda Dharm Industry Co Ltd | |
IT1250749B (it) | 1991-08-02 | 1995-04-21 | Luso Farmaco Inst | Composti eterociclici ad attivita' a ii antagonista |
US5389632A (en) | 1992-02-24 | 1995-02-14 | Laboratoires Upsa | Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists |
FR2687677B1 (fr) * | 1992-02-24 | 1996-10-11 | Union Pharma Scient Appl | Nouveaux derives de polyazaindenes antagonistes des recepteurs a l'angiotensine ii ; leurs procedes de preparation, compositions pharmaceutiques les contenant. |
US5387747A (en) | 1992-02-24 | 1995-02-07 | Laboratoires Upsa | Triazolopyrimidine derivatives which are angiotensin II receptor antagonists, their methods of preparation and pharmaceutical compositions in which they are present |
IT1263804B (it) | 1993-01-22 | 1996-09-03 | Luso Farmaco Inst | Derivati pirimidinonici fusi con eterocicli azotati ad attivita' a ii antagonista |
GB9406573D0 (en) | 1994-03-31 | 1994-05-25 | Merck Sharp & Dohme | Medicaments |
WO1996040256A1 (en) | 1995-06-07 | 1996-12-19 | G.D. Searle & Co. | Method to treat cardiofibrosis with a combination of an angiotensin ii antagonist and spironolactone |
JPH11507627A (ja) | 1995-06-07 | 1999-07-06 | ジー.ディー.サール アンド カンパニー | 充血性心不全症を処置するためのエポキシ−ステロイド系アルドステロン拮抗物質とアンギオテンシンii拮抗物質との組合せ治療 |
ATE216261T1 (de) | 1995-06-07 | 2002-05-15 | Searle & Co | Kombinationstherapie zur behandlung des kongestiven herzversagens mit spironolacton und angiotensin ii-antagonist |
WO1996040255A2 (en) | 1995-06-07 | 1996-12-19 | G.D. Searle & Co. | Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist |
FR2812876B1 (fr) * | 2000-08-08 | 2002-09-27 | Galderma Res & Dev | Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
SE0101579D0 (sv) | 2001-05-04 | 2001-05-04 | Astrazeneca Ab | New compounds |
US7232828B2 (en) | 2002-08-10 | 2007-06-19 | Bethesda Pharmaceuticals, Inc. | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure |
TW200418835A (en) | 2003-01-24 | 2004-10-01 | Tanabe Seiyaku Co | A pyrazolopyrimidine compound and a process for preparing the same |
US20050065184A1 (en) | 2003-08-29 | 2005-03-24 | Aaipharma Inc. | Method of reducing the risk of oxidative stress |
JP2007520559A (ja) * | 2004-02-03 | 2007-07-26 | アボット・ラボラトリーズ | 治療薬としてのアミノベンゾオキサゾール類 |
GEP20105024B (en) | 2004-06-02 | 2010-06-25 | Takeda Pharmaceuticals Co | Fused heterocyclic compound |
RU2384346C2 (ru) | 2004-06-23 | 2010-03-20 | Зольвай Фармасьютиклз Гмбх | Фармацевтические композиции, содержащие nep-ингибиторы, ингибиторы эндогенной эндотелинпродуцирующей системы и антагонисты at1-рецептора |
US20050288272A1 (en) | 2004-06-23 | 2005-12-29 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and AT1 receptor antagonists |
WO2007013078A2 (en) | 2005-07-27 | 2007-02-01 | Mor Research Applications Ltd. | Inhibition of the renin-angiotensin system for the treatment of renal, vascular and cartilage pathology |
WO2007053406A1 (en) | 2005-10-28 | 2007-05-10 | Novartis Ag | Combinations of antihypertensive and cholesterol lowering agents |
WO2007051007A2 (en) | 2005-10-28 | 2007-05-03 | Novartis Ag | Combination of antihypertensives with cholesterol-lowering agent |
US20080064871A1 (en) | 2006-05-26 | 2008-03-13 | Japan Tobacco Inc. | Production Method of Nitrogen-Containing Fused Ring Compounds |
AU2007319505A1 (en) | 2006-11-09 | 2008-05-22 | Ore Pharmaceuticals Inc. | Breast cancer screening and treatment methods |
US20090012052A1 (en) * | 2006-11-09 | 2009-01-08 | Ore Pharmaceuticals Inc. | Method for treating er+ breast cancer |
BRPI0719060A2 (pt) * | 2006-11-24 | 2014-02-04 | Takeda Pharmaceutical | Composto, prodroga, agente farmacêutico, métodos para inibir um receptor de angiotensina ii e/ou ativar um receptor ativado com proliferador de peroxisoma, e para prevenir ou tratar doenças ou condições, e, uso de um composto |
EP2253630A1 (en) | 2007-05-21 | 2010-11-24 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
CA2703019A1 (en) | 2007-09-20 | 2009-03-26 | University Of Rochester | Method and compositions for treatment or prevention of inflammatory conditions |
PT2268612E (pt) | 2008-03-24 | 2014-11-13 | Novartis Ag | Inibidores de metaloprotease de matriz à base de arilsulfonamidas |
WO2009137465A2 (en) | 2008-05-05 | 2009-11-12 | University Of Rochester | Methods and compositions for the treatment or prevention of pathological cardiac remodeling and heart failure |
PL2384327T3 (pl) | 2009-01-30 | 2013-12-31 | Takeda Pharmaceuticals Co | Związki ze skondensowanym pierścieniem i ich zastosowanie |
-
2010
- 2010-01-29 PL PL10703532T patent/PL2384327T3/pl unknown
- 2010-01-29 EP EP10703532.1A patent/EP2384327B1/en active Active
- 2010-01-29 ME MEP-2013-131A patent/ME01621B/me unknown
- 2010-01-29 GE GEAP201012358A patent/GEP20135961B/en unknown
- 2010-01-29 TW TW99102537A patent/TWI468410B/zh not_active IP Right Cessation
- 2010-01-29 AR ARP100100240A patent/AR075344A1/es unknown
- 2010-01-29 CN CN201310750040.3A patent/CN103788097B/zh not_active Expired - Fee Related
- 2010-01-29 RS RS20130472A patent/RS53012B/en unknown
- 2010-01-29 ES ES10703532T patent/ES2433225T3/es active Active
- 2010-01-29 PT PT107035321T patent/PT2384327E/pt unknown
- 2010-01-29 AU AU2010208863A patent/AU2010208863A1/en not_active Abandoned
- 2010-01-29 KR KR1020117020049A patent/KR20110113758A/ko not_active Application Discontinuation
- 2010-01-29 MX MX2011008058A patent/MX2011008058A/es active IP Right Grant
- 2010-01-29 TW TW103125956A patent/TW201444848A/zh unknown
- 2010-01-29 MA MA34132A patent/MA33071B1/fr unknown
- 2010-01-29 US US13/146,989 patent/US8592431B2/en not_active Expired - Fee Related
- 2010-01-29 UY UY0001032409A patent/UY32409A/es not_active Application Discontinuation
- 2010-01-29 SG SG2011053741A patent/SG173135A1/en unknown
- 2010-01-29 CN CN201080014441.7A patent/CN102369205B/zh not_active Expired - Fee Related
- 2010-01-29 CA CA2750710A patent/CA2750710C/en not_active Expired - Fee Related
- 2010-01-29 MY MYPI2011003554 patent/MY152946A/en unknown
- 2010-01-29 US US12/696,147 patent/US8283353B2/en not_active Expired - Fee Related
- 2010-01-29 DK DK10703532.1T patent/DK2384327T3/da active
- 2010-01-29 JP JP2011525329A patent/JP4892649B1/ja not_active Expired - Fee Related
- 2010-01-29 SI SI201030403T patent/SI2384327T1/sl unknown
- 2010-01-29 NZ NZ594606A patent/NZ594606A/xx not_active IP Right Cessation
- 2010-01-29 PE PE2011001418A patent/PE20120593A1/es not_active Application Discontinuation
- 2010-01-29 WO PCT/JP2010/051651 patent/WO2010087515A1/en active Application Filing
- 2010-01-29 EA EA201101138A patent/EA019823B1/ru not_active IP Right Cessation
-
2011
- 2011-06-30 JP JP2011146858A patent/JP5676379B2/ja not_active Expired - Fee Related
- 2011-07-25 IL IL214283A patent/IL214283A0/en unknown
- 2011-07-27 TN TN2011000368A patent/TN2011000368A1/fr unknown
- 2011-07-29 CL CL2011001848A patent/CL2011001848A1/es unknown
- 2011-07-29 DO DO2011000249A patent/DOP2011000249A/es unknown
- 2011-08-09 US US13/205,967 patent/US8921379B2/en not_active Expired - Fee Related
- 2011-08-11 ZA ZA2011/05867A patent/ZA201105867B/en unknown
- 2011-08-26 CR CR20110463A patent/CR20110463A/es unknown
- 2011-08-29 CO CO11109923A patent/CO6362011A2/es active IP Right Grant
- 2011-08-30 EC EC2011011294A patent/ECSP11011294A/es unknown
-
2012
- 2012-03-27 HK HK12103030.2A patent/HK1162505A1/xx not_active IP Right Cessation
-
2013
- 2013-10-22 US US14/059,868 patent/US9115136B2/en not_active Expired - Fee Related
- 2013-10-25 CY CY20131100941T patent/CY1114530T1/el unknown
- 2013-10-25 HR HRP20131017AT patent/HRP20131017T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20131017T1 (hr) | Spoj kondenziranog prstena i njegove uporabe | |
AR055015A1 (es) | Derivados fusionados de pirazol composicion farmaceutica y uso del compuesto para fabricar medicamentos. | |
SI2961736T1 (en) | Histone demethylase inhibitors | |
RU2011108281A (ru) | Трипиридилкарбоксамидные антагонисты орексиновых рецепторов | |
AR074426A1 (es) | Compuesto de n-(((1s,4s,6s)-3-(2-piridinilcarbonil)3-azabiciclo (4,1.0)hept-4-il) metil)-2-heteroarilamina, su uso para la prepracion de un medicamento para el tratamiento de una enfermedad que requiere un antagonista de un receptor de orexina humana y composicion farmaceutica que lo comprende | |
CA2597069A1 (en) | Pyridazine derivatives and their use as therapeutic agents | |
JP2010077137A5 (hr) | ||
JP2008513516A5 (hr) | ||
JP2008513506A5 (hr) | ||
JP2006508065A5 (hr) | ||
CA2634676A1 (en) | Trisubstituted amine compounds as inhibitors of cholesteryl ester transfer protein cetp | |
JP2009538897A5 (hr) | ||
JP2008513496A5 (hr) | ||
RU2014103587A (ru) | Производные циклических аминов в качестве антагонистов рецептора ер4 | |
RU2006105717A (ru) | Производные пиперазина и их применение в качестве терапевтических агентов | |
CA2646962A1 (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
RS50755B (sr) | Supstituisani aril i heteroaril derivati kao modulatori metabolizma i profilakse i lečenje poremećaja proisteklih iz toga | |
AR050208A1 (es) | Compuesto de heteroaril sulfonamida sustituida, procedimiento para la preparacion del mismo, composicion farmaceutica que lo comprende y su uso para preparar un medicamento | |
RU2015101115A (ru) | Гетероароматическое циклическое производное с алкильной разветвленной цепью | |
JP2012528822A5 (hr) | ||
RU2014120373A (ru) | Соединения азетидина, композиции и их применение в качестве ингибиторов растворимой эпоксидгидролазы | |
DE602004006891D1 (de) | Derivate von n-äphenyl(pyrrolidin-2-yl)methylübenzamid und n-ä(azepan-2-yl)phenylmethylübenzamid, verfahren zu deren herstellung und deren anwendung in therapeutika | |
AR072900A1 (es) | Agentes terapeuticos derivados de pirazolo[3,4-d]pirimidina | |
ATE502936T1 (de) | 2, 6-di-(hetero-)aryl-4-amido-pyrimidine als adenosin-rezeptor-antagonisten | |
RU2014144951A (ru) | Новое 1-замещенное производное индазола |